These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 17476141

  • 1. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [Abstract] [Full Text] [Related]

  • 2. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P, Velasco A, Bolaños M, del Mar Perez M, Mel JR, Reina JJ, Rodríguez-Jaraiz MA, Chaves M, González-Barón M.
    Urol Oncol; 2004 Jun 15; 22(1):32-5. PubMed ID: 14969801
    [Abstract] [Full Text] [Related]

  • 4. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, Dimopoulos AM.
    Urology; 2005 Aug 15; 66(2):382-5. PubMed ID: 16098366
    [Abstract] [Full Text] [Related]

  • 5. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM.
    Cancer; 2006 Sep 01; 107(5):1093-100. PubMed ID: 16888761
    [Abstract] [Full Text] [Related]

  • 6. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.
    Clin Cancer Res; 2005 Jan 01; 11(1):284-9. PubMed ID: 15671557
    [Abstract] [Full Text] [Related]

  • 7. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M, Pouessel D, Avancès C, Iborra F, Rebillard X, Faix A, Ségui B, Delbos O, Ayuso D, Culine S.
    Prog Urol; 2006 Jun 01; 16(3):320-3. PubMed ID: 16821344
    [Abstract] [Full Text] [Related]

  • 8. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.
    Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, Oudard S.
    Ann Oncol; 2004 Nov 01; 15(11):1613-21. PubMed ID: 15520061
    [Abstract] [Full Text] [Related]

  • 9. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.
    BJU Int; 2008 Feb 01; 101(3):308-12. PubMed ID: 18184327
    [Abstract] [Full Text] [Related]

  • 10. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE.
    J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A, Inoue A, Yokoi S, Nozumi K, Miyazaki K, Hosoki S, Nagata M, Yamaguchi K.
    Int J Urol; 2009 Aug 07; 16(8):687-91. PubMed ID: 19602005
    [Abstract] [Full Text] [Related]

  • 12. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 13. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
    Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6094-9. PubMed ID: 17062685
    [Abstract] [Full Text] [Related]

  • 14. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M, Kovacic K, Kraljic I, Tarle M.
    Anticancer Res; 2001 Oct 15; 21(2B):1475-9. PubMed ID: 11396235
    [Abstract] [Full Text] [Related]

  • 15. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY, Chi KN.
    Can J Urol; 2006 Dec 15; 13(6):3335-9. PubMed ID: 17187697
    [Abstract] [Full Text] [Related]

  • 16. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K, Miura N, Azuma K, Karashima T, Kasahara K, Nakatsuzi H, Hashine K, Sumiyoshi Y.
    Hinyokika Kiyo; 2007 Feb 15; 53(2):99-104. PubMed ID: 17352158
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK.
    Cancer; 2006 Sep 01; 107(5):975-81. PubMed ID: 16862573
    [Abstract] [Full Text] [Related]

  • 19. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK.
    J Clin Oncol; 2005 Mar 01; 23(7):1439-46. PubMed ID: 15735119
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.